EXO Biologics hopes to gain conditional marketing from Phase I/II BPD trial
EXO Biologics is hoping to receive conditional market approval from the European Medicines Agency (EMA) for its bronchopulmonary dysplasia (BPD) preventative EXOB-001 in preterm newborns if the Phase I/II trial is successful. CEO Hugues Wallemacq of …